The development of increasingly powerful methods to stimulate anti-tumor immune responses carries the risk of breaking tolerance to self and causing autoimmune pathology. How concerned should we be?
This is a preview of subscription content, log in via an institution to check access.
References
Mackay, C. R. Curr. Opin. Immunol. 5, 423–427 (1993).
Banchereau, J. et al. Annu. Rev. Immunol. 18, 767–811 (2000).
Schild, H., Rotzschke, O., Kalbacher, H. & Rammensee, H.G. Science 247, 1587–1589 (1990).
Morgan, D. J. et al. J. Immunol. 160, 643–651 (1998).
Sandberg, J. K. et al. J. Immunol. 165, 25–33 (2000).
Poplonski, L. et al. Eur. J. Immunol. 26, 601–609 (1996).
Heiser, A. et al. J. Immunol. 164, 5508–5514 (2000).
Zinkernagel, R. M. Science 271, 173–178 (1996).
Oldstone, M. B. A., Nerenberg, M., Southern, P., Price, J. & Lewicki, H. Cell 65, 319–331 (1991).
Ohashi, P. S. et al. Cell 65, 305–317 (1991).
Ludewig, B. et al. J. Exp. Med. 191, 795–804 (2000).
Steinman, R. M., Turley, S., Mellman, I. & Inaba, K. J. Exp. Med. 191, 411–416 (2000).
Shevach, E. M. J. Exp. Med. 193, 41–46 (2001).
Waldmann, H. & Cobbold, S. Immunity 14, 399–406 (2001).
Matzinger, P. Annu. Rev. Immunol. 12, 991–1045 (1994).
Gilboa, E. Immunity 11, 263–270 (1999).
Naftzger, C. et al. Proc. Natl Acad. Sci. USA 93, 14809–14814 (1996).
Overwijk, W.W. et al. Proc. Natl Acad. Sci. USA 96, 2982–2987 (1999).
Fong, L., Ruegg, C. L., Brockstedt, D., Engleman, E. G. & Laus, R. J. Immunol. 159, 3113–3117 (1997).
Dittel, B. N., Visintin, I., Merchant, R. M. & Janeway, C. A. Jr J. Immunol. 163, 32–39 (1999).
Dranoff, G. et al. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).
Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. J. Exp. Med. 184, 465–472 (1996).
Zitvogel, L. et al. Nature Med. 4, 594–600 (1998).
van Elsas, A., Hurwitz, A. A. & Allison, J. P. J. Exp. Med. 190, 355–366 (1999).
Albert, M. L. et al. Nature Med. 4, 1321–1324 (1998).
Srivastava, P. K. Semin. Immunol. 8, 295–302 (1996).
Bronte, V. et al. Cancer Res. 60, 253–258 (2000).
Hu, J. et al. J. Exp. Med. 177, 1681–1690 (1993).
Melero, I. et al. J. Virol. 71, 3998–4004 (1997).
Schreurs, M. W. et al. Cancer Res. 60, 6995–7001 (2000).
Vierboom, M. P. M. et al. J. Exp. Med. 186, 695–704 (1997).
Bachmann, M. F., Kundig, T. M., Hengartner, H. & Zinkernagel, R. M. Proc. Natl Acad. Sci. USA 94, 640–645 (1997).
Matzinger, P. Semin. Immunol. 10, 399–415 (1998).
Speiser, D. E. et al. J. Exp. Med. 186, 645–653 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gilboa, E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2, 789–792 (2001). https://doi.org/10.1038/ni0901-789
Issue Date:
DOI: https://doi.org/10.1038/ni0901-789
- Springer Nature America, Inc.
This article is cited by
-
Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer—A Phase I-II Study
Pathology & Oncology Research (2014)
-
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
Molecular Therapy (2013)
-
Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma
BMC Immunology (2011)
-
Harnessing the immune response to treat cancer
Oncogene (2010)
-
How do Tumors Actively Escape from Host Immunosurveillance?
Archivum Immunologiae et Therapiae Experimentalis (2010)